Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,743,221
  • Shares Outstanding, K 106,017
  • Annual Sales, $ 464,370 K
  • Annual Income, $ -139,670 K
  • EBIT $ -122 M
  • EBITDA $ -129 M
  • 60-Month Beta 0.97
  • Price/Sales 19.05
  • Price/Cash Flow N/A
  • Price/Book 7.73

Options Overview Details

View History
  • Implied Volatility 26.48% ( +0.55%)
  • Historical Volatility 42.31%
  • IV Percentile 1%
  • IV Rank 0.61%
  • IV High 115.58% on 04/15/24
  • IV Low 25.94% on 11/18/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 141
  • Volume Avg (30-Day) 349
  • Put/Call OI Ratio 1.32
  • Today's Open Interest 8,223
  • Open Int (30-Day) 9,571

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.05
  • Number of Estimates 7
  • High Estimate 0.22
  • Low Estimate -0.16
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +83.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.76 +11.06%
on 10/23/24
93.45 -11.15%
on 11/11/24
+4.69 (+5.99%)
since 10/18/24
3-Month
70.90 +17.11%
on 10/07/24
93.45 -11.15%
on 11/11/24
+7.30 (+9.64%)
since 08/19/24
52-Week
56.83 +46.12%
on 11/20/23
93.45 -11.15%
on 11/11/24
+25.84 (+45.18%)
since 11/17/23

Most Recent Stories

More News
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

ITCI : 83.17 (+0.85%)
Intra-Cellular Therapies (NASDAQ: ITCI): A Comprehensive Analysis

Company Overview Intra-Cellular Therapies (NASDAQ: ITCI) is a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders. The company’s primary product...

ITCI : 83.17 (+0.85%)
Intra-Cellular Therapies (NASDAQ: ITCI): A Comprehensive Analysis

Company Overview Intra-Cellular Therapies (NASDAQ: ITCI) is a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders. The company’s primary product...

ITCI : 83.17 (+0.85%)
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress

ITCI : 83.17 (+0.85%)
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia

ITCI : 83.17 (+0.85%)
Intra-Cellular: Q3 Earnings Snapshot

Intra-Cellular: Q3 Earnings Snapshot

ITCI : 83.17 (+0.85%)
Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance

ITCI : 83.17 (+0.85%)
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

ITCI : 83.17 (+0.85%)
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed...

ITCI : 83.17 (+0.85%)
XENE : 38.79 (+1.25%)
AXSM : 95.00 (+2.76%)
Intra-Cellular: Q2 Earnings Snapshot

Intra-Cellular: Q2 Earnings Snapshot

ITCI : 83.17 (+0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular...

See More

Key Turning Points

3rd Resistance Point 85.22
2nd Resistance Point 84.41
1st Resistance Point 83.44
Last Price 83.17
1st Support Level 81.67
2nd Support Level 80.86
3rd Support Level 79.89

See More

52-Week High 93.45
Last Price 83.17
Fibonacci 61.8% 79.46
Fibonacci 50% 75.14
Fibonacci 38.2% 70.82
52-Week Low 56.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar